and Human Services (HHS)
EXPIRED
RESPONDING TO CLUB DRUGS AND OTHER EMERGING AND CURRENT DRUG ABUSE TRENDS
Release Date: January 25, 2001
RFA: RFA-DA-01-010
National Institute on Drug Abuse
(http://www.nida.nih.gov)
Letter of Intent Receipt Date: March 16, 2001
Application Receipt Date: April 16, 2001
THIS REQUEST FOR APPLICATIONS (RFA) USES THE "MODULAR GRANT" AND "JUST-IN-
TIME" CONCEPTS. IT INCLUDES DETAILED MODIFICATIONS TO STANDARD APPLICATION
INSTRUCTIONS THAT MUST BE USED WHEN PREPARING THE APPLICATION IN RESPONSE TO
THIS RFA.
PURPOSE
The National Institute on Drug Abuse (NIDA) invites applications for research
projects responding to emerging and current drug abuse trends. The recent
alarming increase in the use of "club drugs" (such as "ecstasy,"
methamphetamine, GHB, and Ketamine), increase in the use of anabolic steroids
among high school students, and the reported use of heroin among adolescents
and young adults illustrate the varied and dynamic nature of contemporary
drug abuse trends. National and community-based reporting systems reveal
regional and local variation in these trends. "Current" trends are included
in this RFA in recognition that a trend that is emerging in one area may be
well-entrenched or "current" elsewhere. New drugs of abuse and new patterns
of use of drugs may emerge rapidly or may gradually diffuse across
communities and populations providing a window of opportunity for
intervention to prevent further escalation of the pattern and to reduce the
health, social, and behavioral consequences. The current state of
scientific knowledge concerning the specific patterns and dynamics of
contemporary drug abuse trends and associated consequences is somewhat
limited. This information is essential to effective and timely local
community-based public health response. This RFA will support research to
characterize the nature and extent of emerging/current drug abuse trends
within local contexts and identify associated health, social, and behavioral
consequences; to elucidate individual, social, cultural, and contextual
factors influencing drug using behaviors; to enhance our ability to identify,
monitor, and assess emerging drug abuse trends; to reveal processes and
patterns of development and diffusion of new drug trends; and to identify
community- or context-specific prevention and health services needs and
interventions.
An RFA, "Research on GHB and its Precursors," DA-01-014, has been issued
concurrently with this RFA. Applicants whose research interests appear to be
suited to both DA-01-014 and the present RFA may wish to contact NIDA program
staff listed under INQUIRIES.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas. This RFA, "Responding to
Club Drugs and Other Emerging and Current Drug Abuse Trends," is related to
one or more of the priority areas. Potential applicants may obtain a copy of
"Healthy People 2010" at http://www.health.gov/healthypeople/.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign, for-profit and non-
profit organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of state and local governments, and eligible
agencies of the federal government. Foreign institutions are not eligible
for R03 grants. Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators. Awards to
foreign institutions under R-series awards are generally limited to 3 years.
MECHANISM OF SUPPORT
This RFA will use the National Institutes of Health (NIH) research project
(R01), small grant (R03), and exploratory/developmental (R21) award
mechanisms. The total project period for an application submitted in
response to this RFA may not exceed five years for the R01, two years for the
R03, and three years for the R21. This RFA is a one-time solicitation.
Future unsolicited competing continuation applications will compete with all
investigator-initiated applications and be reviewed according to the
customary peer review procedures. The anticipated award date is September
30, 2001.
For research in methods development, the R03 or R21 mechanisms are
particularly appropriate. Both are non-renewable and limited in direct cost
amount per year (R03, $50,000; R21, $100,000). The R03 mechanism gives
funding priority to newer, less experienced investigators, investigators at
institutions without well-developed research traditions and resources, or
experienced investigators wishing to change research directions or test new
methods or techniques. The R21 mechanism is intended to encourage
exploratory research projects with sound methodology and strong rationales in
underdeveloped research areas of drug abuse, such as the areas covered in
this RFA. Investigators may also choose to include methods development as
one component within any of the other mechanisms. Responsibility for the
planning, direction, and execution of the proposed project will be solely
that of the applicant. Specific information on individual research
mechanisms can be obtained from the NIDA home page at
http://www.nida.nih.gov/Funding.html.
FUNDS AVAILABLE
NIDA intends to commit approximately $1,500,000 in FY 2001 to fund four to
six new and/or competitive continuation awards in response to this RFA. An
applicant may request a project period of up to five years and a budget for
direct costs of up to $400,000 per year for R01s. Because the nature and
scope of the research proposed may vary, it is anticipated that the size of
each award will also vary. Although the financial plans of NIDA provides
support for this program, awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number of meritorious
applications.
RESEARCH OBJECTIVES
Background
The predominant drug abuse trends, which emerged in the 1990's, include a
broad range of substances with very different pharmacologic properties,
physiologic effects, and potential consequences. The term "club drugs"
refers to drugs that are being used at all-night dance parties, such as
"raves," and in dance clubs. In its Community Drug Alert on Club Drugs
issued in December, 1999 (www.nida.nih.gov/ClubAlert/Clubdrugalert.html),
NIDA describes six club drugs including MDMA ("Ecstasy" or "E"), Gamma-
hydroxybutyrate (GHB), Ketamine, Rohypnol, Methamphetamine, and Lysergic Acid
Diethylamide (LSD). Other substances may also be used in the dance club and
rave contexts. The dance club and rave subcultures appear to be
characterized by an openness to the use of different types of substances,
thus fostering environments for the introduction of new drugs. Drugs may
also be combined, either in one administration or in a sequence, to produce a
sustained or specific desired effect. Research has shown that use of club
drugs can cause serious health problems and, in some cases, death. For
example, the stimulant effects of MDMA, which enable users to dance for
extended periods, may also lead to dehydration and heart failure. Although
the designation "club drugs" suggests a specific context for use, research
suggests that these drugs are used in non-club, non-rave contexts as well.
In April, 2000, NIDA issued a Community Drug Alert in response to the
observed increase in the use of anabolic steroids among adolescents
(www.nida.nih.gov/SteroidAlert/SteroidAlert.html). Research shows that over
time anabolic steroids can take a heavy toll on health, and abuse of oral or
injectable anabolic steroids is associated with increased risk for heart
attacks and strokes. Needle sharing or non-sterile injection techniques
present risks for contracting infections such as HIV, hepatitis B and C, and
bacterial endocarditis.
Reports of increases in the use of heroin among high school and college
students indicate another current trend of public health concern. The
increased availability of consistent high purity heroin suitable for
intranasal use along with decreases in price appear to have led to a wider
acceptance of this drug in young populations in which heroin had not
previously been popular. Evidence in some cities suggests that users may be
transitioning from intra-nasal use to injecting. Increases in heroin-related
emergency department episodes and deaths have been reported in several
cities.
"Trend" refers to a change in specific drug use prevalence over time, as well
as to style or preferences associated with the use of specific drugs. New
drug trends primarily relate to substance specific factors (e.g., the
introduction of newly developed substances or substances not previously
available, changes in mode of administration, new conventions or styles of
use) or population specific factors (e.g., use of a substance in a population
where it had previously not been used, use in a new context, etc.).
In each of the examples of emerging/current trends cited, while there are
indications of the direction of changes in the prevalence of use of specific
drugs, there is limited information about the magnitude of changes and
substance- and population-specific factors. Very little is known about the
characteristics of users of particular drugs; drug use behaviors, contexts,
and norms; factors influencing specific trends; and the health, social, and
behavioral consequences. This information is essential to the identification
of services needs and for the development of timely interventions. A major
objective of this RFA is to address these gaps in our knowledge about
emerging and current trends in order to facilitate the provision of needed
health services and to develop timely and effective interventions tailored to
specific drug using behaviors and contexts. While this RFA encourages
research proposals on the three trends mentioned in this RFA, studies need
not be limited to investigation of these trends.
The identification of emerging trends is affected by the sensitivity of
methods to detect new trends in different populations and across various
locations. New trends have emerged in a broad range of social contexts.
Drug abuse monitoring, timely assessment, and intervention approaches may be
influenced by a range of variables including characteristics of drug users,
pharmacologic and health effects of abused drugs, drug using contexts,
conventions of use of different drugs, and environmental and community
factors. This RFA will support research on models to better understand the
emergence, development, and diffusion of drug trends; and methods for the
early detection and timely assessment of new trends and consequences in
various population subgroups and settings.
This RFA will support community- and context-based epidemiologic (including
ethnographic), prevention, and health services studies on key components of
public health research and response relevant to emerging and current drug use
trends. Researchers are encouraged to incorporate gender analyses, as
appropriate, in the research plan. Studies limited to describing drug use
subcultures without addressing the relevance for health are not within the
scope of this RFA.
Areas of Research Focus
Illustrative examples of research areas within the scope of this RFA are
outlined below. The following examples serve as a guide and are not meant to
subsume all research topics that would be appropriate to the study of
emerging and current trends under this RFA.
o Characterize the nature and extent of specific drug use trends within
local community and/or drug use contexts. Describe context-specific drug use
behaviors, including routes of administration of specific drugs, use of drugs
singly or in combination, timing or sequencing of multiple administrations or
combinations, and/or patterns of social interaction associated with use of
the drug/s. Explore the range of contexts/settings in which drugs are used
(e.g., for club drugs, investigations of use in other settings).
o Describe health, social, and behavioral consequences of use of specific
drugs, drug combinations, and associated behaviors (e.g., continuous dancing
and dehydration). Assess the influence of contextual factors (e.g., in
clubs, outdoor raves, gyms) on consequences.
o Assess the influence of community and contextual factors on drug use and
associated risk behaviors.
o Study the emergence and development of drug trends, and describe processes
of diffusion of drug trends across communities. Particularly of interest is
whether and how club drugs are diffusing out of clubs and specialized sub-
cultural contexts, such as raves, into other contexts and populations.
o Examine the roles of youth social networks, subcultures, and technology
(e.g., Internet) in the development and diffusion of drug trends and in the
dissemination of information about benefits, risks, effects, and consequences
of use of specific drugs and drug combinations.
o Explore how social networks and technology (e.g., Internet) might be used
in preventing use of club drugs.
o Investigate the knowledge, perceptions, attitudes, and norms of drug users
and vulnerable populations with respect to specific drugs and drug use
behaviors. Determine the sources of information on drugs and associated
consequences utilized by drug users, and explore reasons for use and non-use
of specific drugs.
o Examine the marketing, distribution, and sales of drugs, including the
roles of social networks, technology (e.g., Internet, cell phones), and
street-based and situation-based (e.g., clubs, gyms) transactions.
o Develop brief targeted interventions that are population or context
specific; particularly, approaches which can be implemented and administered
quickly and at low cost.
o Develop models for community-based information dissemination. Studies
should assess the role of community and service delivery factors in the
effective and rapid dissemination of public health information and should
result in practical guidance that can be utilized by communities. Assess the
impact of the availability of this public health information on drug use
patterns.
o Assess health services needs and factors impacting provision of services,
particularly as they relate to acute health consequences and the provision of
emergency services.
o Develop models and methods for identification and monitoring of emerging
and current trends (and associated consequences) in different populations and
settings. Studies should consider the impact of various factors such as
location (e.g., urban, rural, suburban), community structure (e.g.,
geographic or political community boundaries; shared identity such as sexual
orientation, ethnicity, recreational preference), and drug using context on
the feasibility of models.
o Develop models and methods for timely verification and assessment of
emerging trends in different populations and contexts.
o Methodological studies on collection of data in different populations and
contexts.
SPECIAL REQUIREMENTS
Meeting
Principal Investigators of grants resulting from this RFA will be asked to
participate in meetings to be convened during the second and third (if
applicable) funding years to report progress, discuss problems, and share
information on emerging and current trends related to the conduct of their
grants. Requests for funds to support attendance at these meetings, to be
held in the Washington, D.C. area, should be included in the budget request.
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that women and members of minority groups and
their sub-populations must be included in all NIH-supported biomedical and
behavioral research projects involving human subjects, unless a clear and
compelling rationale and justification are provided indicating that inclusion
is inappropriate with respect to the health of the subjects or the purpose of
the research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing research involving human subjects should read the
UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research," published in the NIH Guide for Grants and Contracts on
August 2, 2000
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html); a
complete copy of the updated Guidelines is available at
http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm. The
revisions relate to NIH defined Phase III clinical trials and require: a)
all applications or proposals and/or protocols to provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) all investigators to report accrual, and to conduct and report
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by
the NIH, unless there are scientific and ethical reasons not to include them.
This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for
Grants and Contracts, March 6, 1998, and is available at the following URL
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html.
Investigators also may obtain copies of these policies from the program staff
listed under INQUIRIES. Program staff may also provide additional relevant
information concerning these policies.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, Internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Reviewers are cautioned that their anonymity may
be compromised when they directly access an Internet site.
NATIONAL ADVISORY COUNCIL ON DRUG ABUSE RECOMMENDED GUIDELINES FOR THE
ADMINISTRATION OF DRUGS TO HUMAN SUBJECTS
The National Advisory Council on Drug Abuse recognizes the importance of
research involving the administration of drugs to human subjects and has
developed guidelines relevant to such research. Potential applicants are
encouraged to obtain and review the recommendations of the Council before
submitting an application that will administer compounds to human subjects.
The guidelines are available on NIDA's home page at http://www.nida.nih.gov
under Funding or may be obtained by calling (301) 443-2755.
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes a
descriptive title of the proposed research; the name, address, and telephone
number of the Principal Investigator; the identities of other key personnel
and participating institutions; and the number and title of the RFA in
response to which the application is being submitted. Although a letter of
intent is not required, is not binding, and does not enter into the review of
a subsequent application, the information that it contains allows NIDA staff
to plan the review.
Send the letter of intent (by receipt date listed in the heading of this RFA)
to:
Director, Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD 20892-9547
Telephone: (301) 443-2755
FAX: (301) 443-0538
APPLICATION PROCEDURES
The research grant application form PHS 398 (rev. 4/98) is to be used in
applying for these grants. These forms are available at most institutional
offices of sponsored research and from the Division of Extramural Outreach
and Information Resources, National Institutes of Health, 6701 Rockledge
Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, Email:
[email protected].
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
The modular grant concept establishes specific modules in which direct costs
may be requested, as well as a maximum level for requested budgets. Only
limited budgetary information is required under this approach. The
just-in-time concept allows applicants to submit certain information only
when there is a possibility for an award. It is anticipated that these
changes will reduce the administrative burden for the applicants, reviewers,
and Institute staff. The research grant application form PHS 398 (rev. 4/98)
is to be used in applying for these grants, with the modifications noted
below.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
BUDGET INSTRUCTIONS
Modular grant applications will request direct costs in $25,000 modules, up
to a total direct cost request of $250,000 per year. (Applications that
request more than $250,000 direct costs in any year must follow the
traditional PHS 398 application instructions.) The total direct costs must
be requested in accordance with the program guidelines and the modifications
made to the standard PHS 398 application instructions described below:
PHS 398
o FACE PAGE - Items 7a and 7b should be completed, indicating Direct Costs
(in $25,000 increments up to a maximum of $250,000) and Total Costs [Modular
Total Direct plus Facilities and Administrative (F&A) costs] for the initial
budget period. Items 8a and 8b should be completed indicating the Direct and
Total Costs for the entire proposed period of support.
o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page
4 of the PHS 398. It is not required and will not be accepted with the
application.
o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the
categorical budget table on Form Page 5 of the PHS 398. It is not required
and will not be accepted with the application.
o NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget Narrative
page (see http://grants.nih.gov/grants/funding/modular/modular.htm for sample
pages). At the top of the page, enter the total direct costs requested for
each year. This is not a Form page.
Under Personnel, list all project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should
be provided. However, the applicant should use the NIH appropriation
language salary cap and the NIH policy for graduate student compensation in
developing the budget request.
For Consortium/Contractual costs, provide an estimate of total costs (direct
plus facilities and administrative) for each year, each rounded to the
nearest $1,000. List the individuals/organizations with whom consortium or
contractual arrangements have been made, the percent effort of all personnel,
and their role on the project. Indicate whether the collaborating
institution is foreign or domestic. The total cost for a
consortium/contractual arrangement is included in the overall requested
modular direct cost amount. Include the Letter of Intent to establish a
consortium.
Provide an additional narrative budget justification for any variation in the
number of modules requested.
o BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by
reviewers in the assessment of each individual's qualifications for a
specific role in the proposed project, as well as to evaluate the overall
qualifications of the research team. A biographical sketch is required for
all personnel, following the instructions below. No more than three pages
may be used for each person. A sample biographical sketch may be viewed at:
http://grants.nih.gov/grants/funding/modular/modular.htm.
- Complete the educational block at the top of the form page;
- List position(s) and any honors;
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years;
and
- List selected peer-reviewed publications with full citations.
o CHECKLIST - This page should be completed and submitted with the
application. If the F&A rate agreement has been established, indicate the
type of agreement and the date. All appropriate exclusions must be applied
in the calculation of the F&A costs for the initial budget period and all
future budget years.
The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information
is necessary following the initial review.
The RFA label available in the PHS 398 (rev. 4/98) application form must be
affixed to the bottom of the face page of the application. Type the RFA
number on the label. Failure to use this label could result in delayed
processing of the application such that it may not reach the review committee
in time for review. In addition, the RFA title and number must be typed on
line 2 of the face page of the application form, and the YES box must be
marked.
The sample RFA label available at
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified to
allow for this change. Please note this is in pdf format.
Submit a signed, typewritten original of the application, including the
Checklist, and three signed photocopies in one package to:
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040, MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application must be
sent to:
Director, Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD 20892-9547
Applications must be received by the application receipt date listed in the
heading of this RFA. If an application is received after that date, it will
be returned to the applicant without review.
The Center for Scientific Review (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application. The
CSR will not accept any application that is essentially the same as one
already reviewed. This does not preclude the submission of substantial
revisions of applications already reviewed, but such applications must
include an introduction addressing the previous critique.
REVIEW CONSIDERATIONS
Upon receipt, applications will be reviewed for completeness by the CSR and
for responsiveness by the NIDA. Incomplete and/or non-responsive
applications will be returned to the applicant without further consideration.
Applications that are complete and responsive to the RFA will be evaluated
for scientific and technical merit by an appropriate peer review group
convened by NIDA in accordance with the review criteria stated below. As
part of the initial merit review, all applications will receive a written
critique and undergo a process in which only those applications deemed to
have the highest scientific merit, generally the top half of the applications
under review, will be discussed, assigned a priority score, and receive a
second level review by National Advisory Council on Drug Abuse.
Review Criteria
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments reviewers will be asked to discuss the following aspects
of the application in order to judge the likelihood that the proposed
research will have a substantial impact on the pursuit of these goals. Each
of these criteria will be addressed and considered in assigning the overall
score, weighting them as appropriate for each application. Note that the
application does not need to be strong in all categories to be judged likely
to have major scientific impact and thus deserve a high priority score. For
example, an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
(1) Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
(2) Approach: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
(3) Innovation: Does the project employ novel concepts, approaches, or
methods? Are the aims original and innovative? Does the project challenge
existing paradigms or develop new methodologies or technologies?
(4) Investigator: Is the investigator appropriately trained and well suited
to carry out this work? Is the work proposed appropriate to the experience
level of the principal investigator and other researchers (if any)?
(5) Environment: Does the scientific environment in which the work will be
done contribute to the probability of success? Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements? Is there evidence of institutional
support?
In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:
o The adequacy of plans to include both genders, minorities and their
subgroups, and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated.
o The reasonableness of the proposed budget and duration in relation to the
proposed research.
o The adequacy of the proposed protection for humans, animals, or the
environment, to the extent they may be adversely affected by the project
proposed in the application.
o The adequacy of the proposed plan to share data.
Schedule
Letter of Intent Receipt Date: March 16, 2001
Application Receipt Date: April 16, 2001
Peer Review Date: June/July 2001
Council Review: September 2001
Earliest Anticipated Start Date: September 30, 2001
AWARD CRITERIA
Award criteria that will be used to make award decisions include scientific
merit (as determined by peer review), availability of funds, and programmatic
priorities.
INQUIRIES
Inquiries concerning this RFA are encouraged. The opportunity to clarify any
issues or answer questions from potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
Moira O Brien, M.Phil.
Division of Epidemiology, Services, and Prevention Research
National Institute on Drug Abuse
6001 Executive Boulevard, Room 5153, MSC 9589
Bethesda, MD 20892-9589
Telephone: (301) 402-1881
FAX: (301) 443-2636
E-mail: [email protected]
Direct inquiries regarding review issues to:
Teresa Levitin, Ph.D.
Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD 20892-9547
Telephone: (301) 443-2755
FAX: (301) 443-0538
E-mail: [email protected]
Direct inquiries regarding fiscal matters to:
Gary Fleming, J.D., M.A.
Grants Management Branch
Office of Planning and Resource Management
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD 20892-9541
Telephone: (301) 443-6710
FAX: (301) 594-6847
E-mail: [email protected]
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance No.
93.279. Awards are made under authorization of Sections 301 and 405 of the
Public Health Service Act as amended (42 USC 241 and 284) and administered
under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts
74 and 92. This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and promote the non-use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
| ||||||
|
|
|
Department of Health and Human Services (HHS) |
|
|||
|
NIH... Turning Discovery Into Health® |
||||||